Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo

Metastatic colorectal cancer (mCRC) is the second leading cause of cancer deaths in the United States. More than 50% of patients with mCRC harbor mutations of the oncogenic driver RAS (KRAS or NRAS). Because directly targeting most mutations of RAS is technically challenging, researchers have concen...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Fan, Ghosh, Susmita, Powell, Reid, Roszik, Jason, Park, Yongsun, Sobieski, Mary, Sorokin, Alexey, Stephan, Clifford, Kopetz, Scott, Ellis, Lee M., Bhattacharya, Rajat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035898/
https://www.ncbi.nlm.nih.gov/pubmed/36952536
http://dx.doi.org/10.1371/journal.pone.0281063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035898/
https://www.ncbi.nlm.nih.gov/pubmed/36952536
http://dx.doi.org/10.1371/journal.pone.0281063

Ejemplares similares